Cargando…

Metabolic effect and receptor signalling profile of a non-metabolisable insulin glargine analogue

CONTEXT: Insulin glargine (GLA) is rapidly metabolized in vivo to metabolite M1, which has in vitro metabolic and mitogenic profiles comparable with human insulin (HI). OBJECTIVE: To investigate the pharmacologic and signalling profiles of a non-metabolizable analogue (A21Gly,DiD-Arg) insulin (D-GLA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Werner, Ulrich, Korn, Marcus, Schmidt, Ronald, Wendrich, Thomas M., Tennagels, Norbert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Informa UK Ltd. 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219851/ https://www.ncbi.nlm.nih.gov/pubmed/25144413 http://dx.doi.org/10.3109/13813455.2014.950589

Ejemplares similares

The metabolic and mitogenic properties of basal insulin analogues
por: Tennagels, Norbert, et al.
Publicado: (2013)

Differences in metabolic and mitogenic signalling of insulin glargine and insulin aspart B10 in rats
por: Tennagels, N., et al.
Publicado: (2013)

Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function
por: Hartmann, Thorsten, et al.
Publicado: (2016)

Erratum to: Differences in metabolic and mitogenic signalling of insulin glargine and AspB10 human insulin in rats
por: Tennagels, N., et al.
Publicado: (2013)

In Vitro Metabolic and Mitogenic Signaling of Insulin Glargine and Its Metabolites
por: Sommerfeld, Mark R., et al.
Publicado: (2010)

Concentrations of Insulin Glargine and Its Metabolites During Long-Term Insulin Therapy in Type 2 Diabetic Patients and Comparison of Effects of Insulin Glargine, Its Metabolites, IGF-I, and Human Insulin on Insulin and IGF-I Receptor Signaling
por: Varewijck, Aimee J., et al.
Publicado: (2013)

Effect of Insulin Analogues on Insulin/IGF1 Hybrid Receptors: Increased Activation by Glargine but Not by Its Metabolites M1 and M2
por: Pierre-Eugene, Cécile, et al.
Publicado: (2012)

Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs
por: Werner, Ulrich, et al.
Publicado: (2020)

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
por: Steinstraesser, A, et al.
Publicado: (2014)

Evaluation of the innate immunostimulatory potential of originator and non-originator copies of insulin glargine in an in vitro human immune model
por: Luna, Ernesto, et al.
Publicado: (2018)

Insulin Receptor Phosphorylation by Endogenous Insulin or the Insulin Analog AspB10 Promotes Mammary Tumor Growth Independent of the IGF-I Receptor
por: Gallagher, Emily Jane, et al.
Publicado: (2013)

Insulin glargine overdose
por: Doğan, Fatma Sarı, et al.
Publicado: (2012)

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
por: Linnebjerg, Helle, et al.
Publicado: (2016)

Renalase, a catecholamine-metabolising enzyme?
por: Boomsma, F., et al.
Publicado: (2007)

Purine-Metabolising Enzymes and Apoptosis in Cancer
por: Camici, Marcella, et al.
Publicado: (2019)

The signalling conformation of the insulin receptor ectodomain
por: Weis, Felix, et al.
Publicado: (2018)

Metabolism of Insulin Glargine After Repeated Daily Subcutaneous Injections in Subjects With Type 2 Diabetes
por: Lucidi, Paola, et al.
Publicado: (2012)

Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients
por: Jakobsen, Marie, et al.
Publicado: (2012)

Insulin glargine and the risk of cancer
por: Ahmed, FA
Publicado: (2010)

Bacteroides fragilis metabolises exopolysaccharides produced by bifidobacteria
por: Rios-Covian, David, et al.
Publicado: (2016)

The Role of Insulin Glargine and Human Insulin in the Regulation of Thyroid Proliferation Through Mitogenic Signaling
por: Sheng, Xiaoli, et al.
Publicado: (2019)

Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
por: Tarigan, Tri Juli Edi, et al.
Publicado: (2021)

High abundance of sugar metabolisers in saliva of children with caries
por: Manzoor, Muhammed, et al.
Publicado: (2021)

Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs
por: Poon, Kitty, et al.
Publicado: (2010)

Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes
por: Bolli, Geremia B., et al.
Publicado: (2012)

A case of hypersensitivity to soluble and isophane insulins but not to insulin glargine
por: Belhekar, Mahesh N., et al.
Publicado: (2015)

Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study
por: Ruiter, R., et al.
Publicado: (2011)

Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine
por: Hadjiyianni, I., et al.
Publicado: (2016)

Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus
por: Wang, Weimin, et al.
Publicado: (2022)

A Model System for Examining the Radiosensitivity of Metabolising Layers of Cells
por: Scott, O. C. A.
Publicado: (1957)

Exploring the role of drug-metabolising enzymes in antidepressant side effects
por: Hodgson, Karen, et al.
Publicado: (2015)

Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus
por: Ilag, L. L., et al.
Publicado: (2016)

Insulin Glargine: A Reevaluation of Rodent Carcinogenicity Findings
por: Stammberger, Ingo, et al.
Publicado: (2012)

A Salutary Tale—Glargine insulin and cancer risk
por: Boyle, Peter
Publicado: (2009)

Insulin Glargine and Acarbose in the treatment of elderly patients with diabetes
por: Li, Jing, et al.
Publicado: (2019)

Insulin-glargine/norepinephrine: Lack of efficacy: case report
Publicado: (2022)

Protocol to Assess the Biological Activity of Insulin Glargine, Insulin Lispro, and Insulin Aspart In Vitro
por: Garige, Mamatha, et al.
Publicado: (2023)

Engineering of Insulin Receptor Isoform-Selective Insulin Analogues
por: Glendorf, Tine, et al.
Publicado: (2011)

A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide
por: Frias, Juan P., et al.
Publicado: (2018)

The Expression and Prognostic Significance of Retinoic Acid Metabolising Enzymes in Colorectal Cancer
por: Brown, Gordon T., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_iqhb4qbp0j4ff00aq7jvk6efgc